Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys

World Psychiatry, Journal Year: 2017, Volume and Issue: 16(3), P. 299 - 307

Published: Sept. 21, 2017

Substance use is a major cause of disability globally. This has been recognized in the recent United Nations Sustainable Development Goals (SDGs), which treatment coverage for substance disorders identified as one indicators. There have no estimates this cross‐nationally, making it difficult to know what baseline that SDG target. Here we report data from World Health Organization (WHO)'s Mental Surveys (WMHS), based on representative community household surveys 26 countries. We assessed 12‐month prevalence (alcohol or drug abuse/dependence); proportion people with these who were aware they needed and wished receive care; those seeking care received it; such met minimal standards quality (“minimally adequate treatment”). Among 70,880 participants, 2.6% criteria disorders; was higher upper‐middle income (3.3%) than high‐income (2.6%) low/lower‐middle (2.0%) Overall, 39.1% need; recognition more common (43.1%) (35.6%) (31.5%) need, 61.3% made at least visit service provider, 29.5% latter minimally exposure (35.3% high, 20.3% upper‐middle, 8.6% countries). only 7.1% past‐year treatment: 10.3% high income, 4.3% 1.0% These suggest small minority even treatment. At three barriers are involved: awareness/perceived accessing once need recognized, compliance (on part both provider client) obtain Various factors likely be involved each barriers, all addressed improve disorders. provide global monitoring progress an indicator within SDGs.

Language: Английский

---

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal

Neuropsychopharmacology, Journal Year: 2017, Volume and Issue: 43(1), P. 173 - 194

Published: Sept. 6, 2017

Language: Английский

---

Adolescent drug exposure: A review of evidence for the development of persistent changes in brain function

Brain Research Bulletin, Journal Year: 2020, Volume and Issue: 156, P. 105 - 117

Published: Jan. 8, 2020

Language: Английский

---

An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2019, Volume and Issue: 269(1), P. 73 - 86

Published: Jan. 2, 2019

Language: Английский

---

Pharmacotherapies for cannabis dependence

Cochrane library, Journal Year: 2019, Volume and Issue: 2020(3)

Published: Jan. 28, 2019

Language: Английский

---

Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study

American Journal on Addictions, Journal Year: 2017, Volume and Issue: 26(2), P. 136 - 144

Published: Feb. 2, 2017

Background and Objectives Recent evidence suggests that women may fare worse than men in cannabis trials with pharmacologic interventions. Identifying baseline clinical profiles of treatment-seeking cannabis-dependent adults could inform gender-specific treatment planning development. Methods The current study compared demographic, use, psychiatric factors between (n = 86) 216) entering the Achieving Cannabis Cessation−Evaluating N-acetylcysteine Treatment (ACCENT) study, a multi-site, randomized controlled trial conducted within National Drug Abuse Clinical Trials Network. Results Women reported greater withdrawal intensity (p .001) negative impact .001), predominantly due to physiological mood symptoms. were more likely have lifetime panic disorder .038) agoraphobia .022), days poor physical health .006) cannabis-related medical problems .023). reporting chronic pain had mean scores .006). Men did not differ on any measures use. Discussion Conclusions Cannabis-dependent present for severe impairing symptoms conditions men. This might help explain recent suggesting Baseline can Scientific Significance benefit from integrated focusing co-occurring disorders targeted syndrome.(Am J Addict 2017;26:136–144)

Language: Английский

---

Opioid and Cannabis Co-Use among Adults With Chronic Pain: Relations to Substance Misuse, Mental Health, and Pain Experience

Journal of Addiction Medicine, Journal Year: 2018, Volume and Issue: 13(4), P. 287 - 294

Published: Dec. 20, 2018

Opioid misuse constitutes a significant public health problem and is associated with host of negative outcomes. Despite efforts to curb this increasing epidemic, opioids remain the most widely prescribed class medications. Prescription are often used treat chronic pain despite risks use, remains an important factor in understanding epidemic. Cannabis another substance that has recently garnered attention literature, as numbers individuals use cannabis manage pain. Importantly, co-use substances generally poorer outcomes than single yet little work examined impact opioid-cannabis co-use.The current study alone, compared opioid co-use, among adults (n = 450) on mental health, pain, outcomes.Results suggest that, was elevated anxiety depression symptoms, well tobacco, alcohol, cocaine, sedative problems, but not experience.These findings highlight vulnerable population polysubstance users indicates need for more comprehensive assessment treatment

Language: Английский

---

Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms

Cannabis and Cannabinoid Research, Journal Year: 2020, Volume and Issue: 5(2), P. 132 - 144

Published: Feb. 11, 2020

Introduction: Cannabinoids have long been known for their ability to treat nausea and vomiting. Recent reports, however, highlighted the paradoxical proemetic effects of cannabinoids. Cannabinoid hyperemesis syndrome (CHS) is characterized by cyclical episodes vomiting, accompanied abdominal pain following prolonged, high-dose cannabis use, which alleviated hot baths showers. Little about cause this syndrome. Discussion: produce a biphasic effect on with low doses having an antiemetic high producing emesis. Presentation treatment CHS are similar vomiting as well chemotherapy-related anticipatory suggesting that these phenomena may share mechanisms. The prevalence not because symptomatic overlap other disorders lack knowledge public physicians. Treatment typical drugs ineffective CHS, but anxiolytic sedative drugs, along showers, seem be consistently effective at reducing symptoms. only way permanently end abstinence from Case studies limited pre-clinical data indicate prolonged main psychotropic compound in cannabis, Δ9-tetrahydrocannabinol (THC), result changes endocannabinoid system acting cannabinoid 1 (CB1) receptor. These can dysregulate stress anxiety responses, thermoregulation, transient receptor potential vanilloid system, several neurotransmitters systems, thus candidates mediating pathophysiology CHS. Conclusions: Excessive administration disrupts normal functioning More clinical research needed fully understand underlying disorder negative consequences use.

Language: Английский

---

Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016

Journal of Managed Care & Specialty Pharmacy, Journal Year: 2020, Volume and Issue: 26(3), P. 246 - 252

Published: Feb. 27, 2020

BACKGROUND: Gabapentin is prescribed for a variety of conditions and often used off label. It important to understand the prevalence gabapentin prescribing characteristics individuals who are gabapentin, given increasing concern regarding its potential misuse. OBJECTIVES: To (a) examine state- region-level trends in from 2009 2016 (b) characterize demographic clinical nationwide population commercially insured adults. METHODS: This retrospective, longitudinal study examined 2016. The included aged 18-64 years were enrolled commercial insurance plan at any point Individuals defined as beneficiaries with least 1 prescription claim calendar year (CY). A cross-sectional descriptive analysis was performed differences or not CY RESULTS: nearly doubled During this time, increased every state (range: 44%-179%). State-specific rates varied 12.7 43.9 per 1,000 beneficiaries. Overall, 2.7% filled ≥ more likely fill opioid prescriptions (60.8% vs. 16.5%, P < 0.01); reside South (53.7% 47%, be female (62.5% 52.3%, 55-64 (41.7% 21.2%, 0.01) compared comparator. also had significantly higher seizure disorders, neuropathic pain, mental health substance use diabetes. CONCLUSIONS: among U.S. privately has steadily recent years. Additional research should coprescribing context epidemic. DISCLOSURES: project described supported by NIH National Center Advancing Translational Sciences through grant number UL1TR001998. partially 2017-PM-BX-K026 (Data-Driven Responses Prescription Drug Misuse Kentucky) awarded Bureau Justice Assistance. Viewpoints opinions document those authors do necessarily represent official position policies Department views NIH. have conflicts interest report. Portions been previously presented poster presentations 2019 Academy Health Annual Research Meeting; June 2-4, 2019; Washington, DC, University Kentucky Substance Use Day; March 3, Lexington, KY.

Language: Английский

---

The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda

Drug and Alcohol Dependence, Journal Year: 2020, Volume and Issue: 212, P. 107993 - 107993

Published: April 27, 2020

Language: Английский

---